等离子体获得Prothya生物溶液,以扩大全球等离子体治疗的覆盖面。 Accord Plasma acquires Prothya Biosolutions to expand global plasma therapy access.

作为Intas药品公司的一个部门,Accord Plasma B.V.已完成收购Prothya Biosolutions Belgium,这是一家主要的欧洲血分离器,在阿姆斯特丹,布鲁塞尔和匈牙利设有设施. Accord Plasma B.V., a unit of Intas Pharmaceuticals, has completed its acquisition of Prothya Biosolutions Belgium, a major European plasma fractionator with facilities in Amsterdam, Brussels, and Hungary. 将普罗西亚的1200名雇员和业务活动纳入协议网络的这项交易加强了血浆衍生药物的全球生产和分销。 The deal, which brings Prothya’s 1,200 employees and operations into Accord’s network, enhances global production and distribution of plasma-derived medicines. 通过将普罗西亚的欧洲专长与印度的Intas制造业规模相结合,《协议》的目的是改善全世界获得基本、高质量等离子疗法的机会。 By combining Prothya’s European expertise with Intas’s manufacturing scale in India, Accord aims to improve access to essential, high-quality plasma therapies worldwide. 这一举动支持了对这些往往得不到充分处方的治疗的日益增长的需求。 The move supports growing demand for these often under-prescribed treatments. 协议保健全球首席执行官保罗·特雷德韦尔(Paul Tredwell)强调该公司致力于在超过85个国家推广可靠和负担得起的等离子疗法。 Paul Tredwell, Global CEO of Accord Healthcare, highlighted the company’s commitment to expanding reliable, affordable plasma therapies across over 85 countries.